舍曲林联合小剂量齐拉西酮治疗强迫症对照研究

A control study of sertraline plus small-dose ziprasidone in obsessive-compulsive disorder

目的探讨舍曲林联合小剂量齐拉西酮治疗强迫症的临床疗效和安全性。方法将76例强迫症患者随机分为研究组和对照组各38例，均口服舍曲林治疗，研究组联合小剂量齐拉西酮治疗，观察12周。于治疗前及治疗4周、8周、12周末采用Yale—Brown强迫量表评定l临床疗效，并随时记录不良反应发生状况。结果治疗后两组Yale—Brown强迫量表总分及各因子分均较治疗前显著下降（P〈0．05或0．01），治疗8周、12周末研究组较对照组下降更显著（P〈0．01）；研究组起效时间显著早于对照组，治疗12周末总有效率显著高于对照组（P〈0．05）；两组不良反应均轻微，发生率比较差异无显著性（P〉0．05）。结论舍曲林联合小剂量齐拉西酮治疗强迫症疗效显著，起效快，不增加不良反应，显著优于单用舍曲林治疗。

Objective To explore the efficacy and safety of sertraline plus small-dose ziprasidone in obsessive-compulsive disorder（OCD）. Methods Seventy-six OCD patients were randomly assigned to two groups of 38 ones each, both groups took orally sertraline and research group was plus small-dose ziprasidone for 12 weeks. Efficacies were assessed with the Yale-Brown Obsessive Compulsive Scale （Y BOCS） at baseline and at the end of the 4th, 8th and 12th week and adverse reactions recorded at any time. Results The total and each factor scores of the Y-BOCS both groups lowered more significantly compared with pretreatment after treatment （P〈0.05 or 0.01） and so did those in research than in control group at the end of the 8th and 12th week （P〈0.01） ; taking-effect time was significantly earlier and total effective rate higher in research than in control group （P〈0.05） ; adverse reactions of both groups were mild and there were no significant differences in incidences （P〈0.05）. Conclusion Sertraline plus small-dose ziprasidone in obsessive-compulsive disorder has an evident effect, takes effect more rapidly, doesn＇t increase adverse reactions, and has an notable advantage over single-use of sertraline.